(NASDAQ: RGNX) Regenxbio's forecast annual revenue growth rate of 26.29% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 79.51%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.97%.
Regenxbio's revenue in 2025 is $156,718,000.On average, 6 Wall Street analysts forecast RGNX's revenue for 2025 to be $11,684,252,074, with the lowest RGNX revenue forecast at $7,594,277,293, and the highest RGNX revenue forecast at $17,315,754,793. On average, 6 Wall Street analysts forecast RGNX's revenue for 2026 to be $11,646,531,489, with the lowest RGNX revenue forecast at $9,430,146,176, and the highest RGNX revenue forecast at $16,557,932,195.
In 2027, RGNX is forecast to generate $17,103,777,146 in revenue, with the lowest revenue forecast at $10,961,040,119 and the highest revenue forecast at $22,781,327,068.